TRANSLATIONAL RELEVANCE
Improved patient stratification using novel genetic prognosticators or response predictors could help individualize prostate cancer therapies. Pre-clinical studies have shown that TMPRSS2-ERG gene fusion, leading to ERG overexpression, may be a biomarker of DNA double strand break repair (DSB) capacity with potential implications for sensitivity to radiotherapy or DNA damaging modifying agents (e.g. PARP inhibitors). About 50% of clinically localized PCa cancers harbor TMPRSS2-ERG gene fusions, leading to ERG overexpression (5) . Newer immunohistochemical (IHC) approaches using ERG-specific antibodies have shown that ERG protein overexpression in situ is a sensitive and specific surrogate for the presence of TMPRSS2-ERG gene fusion detected by FISH or qRT-PCR (1, (6) (7) (8) . If the presence of a fusion, or ERG overexpression, is associated with differential prognosis or treatment response this would have major implications for its clinical use in a cancer that is diagnosed in more than 250,000 men in North America each year (9) .
Intermediate-risk PCa is defined by National Comprehensive Cancer Network (NCCN) as T1/T2-N0-M0 with a Gleason score 7 and PSA < 20 ng/mL or Gleason score < 7 and PSA 10-20 ng/mL.(10) Clinical outcomes are highly heterogeneous within this risk category, with up to 30-40% of patients failing therapy independent of treatment modality (11, 12) . Therefore, identification of additional prognostic factors that could stratify these patients into more precise prognostic or predictive sub-groups based on individual tumor genetics factors would be extremely valuable.
Research. (13) (14) (15) (16) (17) (18) . However, in the largest cohort tested to date ERG overexpression (determined by IHC) was not prognostic for biochemical recurrence following radical prostatectomy (19) . This lack of prognostic significance in surgery patients was confirmed by a recent meta-analysis using biochemical recurrence and disease-specific mortality as endpoints (20) . However, the role of TMPRSS2-ERG as a response modifier in patients receiving modern era radiotherapy has not yet been evaluated.
Precision radiotherapy delivered with image-guidance (IGRT) is an important modality for PCa treatment. Recent pre-clinical data suggest that that TMPRSS2-ERG status may relate to DNA repair and radiotherapy-induced DNA damage. Using fluorescence in situ hybridization (FISH), androgen signaling was found to induce proximity of the TMPRSS2 and ERG genomic loci (both located on chromosome 21q22.2), particularly following induction of DNA double-strand breaks (DSBs) by irradiation or inhibition of topoisomerase II beta (TOP2B) (21, 22) . Other data support fusion status associated with altered sensitivity to DNA damaging agents (23) . Stable overexpression of TMPRSS2-ERG fusion product in PCa cells can alter radiosensitivity, and TMPRSS2-ERG fusion status can render tumor cells sensitive to poly (ADP-ribose) polymerase 1 (PARP1) inhibition in vitro and in vivo (24) . In the latter study, the TMPRSS2-ERG fusion products interacted in a DNA-independent manner with PARP1 and the catalytic subunit of DNA protein kinase, a DSB repair protein. 
MATERIALS AND METHODS

Patient Cohorts and Treatment Delivery
We investigated TMPRSS2-ERG status in pre-treatment biopsies of intermediate- Table 1 and background tumor genetics for this cohort have been described previously (26) .
Clinical characteristics for both aCGH-and IHC-cohorts are presented in Table 1 . To create the IHC-cohort, formalin-fixed paraffin-embedded (FFPE) pre-treatment biopsies from 173 patients were used to construct a biopsy tissue microarray (TMA). Post-array, the cohort was reduced to 118 evaluable patients after a quality assurance protocol, which removed patients if malignant cores could not be scored within the histologic section; if the NCCN criteria of intermediate risk disease was not met (27) ; or if they lacked followup data (see Figure 1B ). were taken during fiducial marker insertion. Staging CT and bone scans were not routinely performed. The clinical target volume (CTV) encompassed the prostate gland alone. The planning target volume (PTV) was defined by a 10 mm margin around the CTV, except posteriorly where the margin was 7 mm. All patients were treated with 6-field conformal or intensity-modulated radiotherapy (IMRT) with image-guidance. The radiotherapy dose was variable within the two cohorts, so doses were converted to biologically effective doses (BED) with an assumed alpha-beta of 1.5 (28) . Dose details are presented in Table 1 for both cohorts. Neoadjuvant and concurrent hormonal therapy (ADT) was used in 33 patients (26%) in the aCGH-cohort and in 35 patients (29%) in the IHC-cohort. This ADT consisted of bicalutamide 150mg daily for 3 months of neoadjuvant treatment followed by a further 2 months as concurrent treatment with radiotherapy (ISRCTN64733264) (29) . Patients were followed at 6 monthly intervals 
aCGH analysis
The biopsy preparation, DNA extraction, aCGH procedure, and copy number detection were previously described (26, 30) . For each patient, the presence of a TMPRSS2-ERG gene fusion was defined as an observation of a 21q22.2-3 genomic deletion. More specifically, a deletion must overlap with the region contained by the 5' and 3' ends of ERG and TMPRSS2, respectively (Supplementary Figure 1) .
Tissue microarray (TMA) and Immunohistochemistry
The biopsy TMA was constructed from pre-treatment prostate biopsies using a "checkerboard" technique as previously described (32) . Benign and malignant prostate tissues within each core were denoted for dissection based on hematoxylin and eosin (H&E)-stained sections by an experienced genitourinary pathologist (TVdK). Based on pathologic markings, 4 mm long "checkers" were cut along the length of the biopsies and flipped 90 degrees and placed within a TMA template (see Supplementary Figure 2 ).
Although 173 patients had diagnostic biopsy blocks available, a pathologic re-assessment was completed in which each checker was confirmed between contiguous slices for the presence or absence of malignancy. After this quality assurance step, and after removing patients lacking follow-up data or who did not present with intermediate-risk disease, a total of 118 patients remained for comparison to clinical parameters and outcome ( Figure   1A ). An assessment of the intra-patient heterogeneity of number of checkers is shown in Figure 2 as evaluated using the Kappa and Fleiss Kappa approaches (33, 34) . This analysis showed that for patients with more than one checker there was significant agreement between ERG staining results.
Immunostaining of the tissue microarrays for ERG was performed as follows: deparaffinized 4 μm sections were dehydrated, blocked in 0.6% hydrogen peroxide in methanol for 20 minutes and processed for antigen retrieval in EDTA (pH 9.0) for 30 minutes in a microwave, followed by 30 minutes of cooling in EDTA buffer. Sections were then blocked in 1% horse serum followed by an overnight incubation with the ERG-MAb mouse monoclonal antibody (Biocare Medical clone 9Fy, Concord, CA), 
Statistical analysis
The primary outcome was biochemical relapse-free rate (bRFR) defined according to Phoenix criteria (PSA nadir + 2 ng/mL) (35) were also tested adjusting for pre-treatment PSA, T category, and Gleason score using Cox proportional hazards regression models. The proportional hazards assumption was checked using Schoenfeld residuals and found to be satisfied for all variables, with the exception of ADT in the aCGH cohort. A time-varying coefficient was added to the Cox model to account for this model violation. All statistical analyses were done using the R statistical environment (v2.12.1). Hazard ratios, 95% confidence intervals and p-values using the Wald test were generated using the survival package version (v2. . A twosided p-value of less than 0.05 was used to assess statistical significance.
Research. 
RESULTS
We designed this study to test whether IGRT patients had a differential prognosis based on fusion status. If true, fusion status would become a novel predictive factor for outcome in patients receiving radiotherapy (but not surgery). The clinical characteristics of both aCGH and IHC-cohorts are presented in Table 1 . These cohorts were comprised by intermediate-risk patients mostly with T2 disease, Gleason score 7 and PSA less than 10 ng/mL. The mean radiation dose was 76Gy. In the aCGH-cohort, 27 of 126 biopsies (21%) were found to be TMPRSS2-ERG fusion-positive. In the IHC-cohort, a positive ERG immunohistochemical staining was observed in 59 (50%) of the cases. We next tested whether fusion status was associated with more aggressive clinical states in our IGRT cohort. ERG overexpression was associated with T-category (T2 vs. T1; P = 0.02);
but not with Gleason score (7 vs. 6; P = 1.00) or pre-treatment PSA (continuous, P = 0.28). TMPRSS2-ERG fusion (aCGH-cohort) was not correlated to any of these clinical variables (Supplementary Tables 2A-F) .
We then tested fusion status as a prognostic factor for biochemical failure following IGRT. At a median follow up of 7.8 years (range 0.8-12.2), 55 patients (44%) in the aCGH-cohort experienced biochemical relapse (see Table 1 The prognostic significance of pre-treatment PSA, T-category and Gleason score for bRFR for both cohorts is shown in Table 2 and Supplementary Figure 3A -F. Only pre-treatment PSA in the aCGH-cohort was prognostic for bRFR. We then added data pertaining to fusion status into the model. TMPRSS2-ERG status, whether assayed by aCGH or IHC, was not prognostic for bRFR following radiotherapy in either univariate or multivariate analyses (see Figure 3A- In concert with other publications showing the potential predictive value of TMPRSS2-ERG status on androgen deprivation therapy response (18, 37, 38) , ERG overexpression was reported to be a factor in the relative response to salvage ADT following surgery (19) . However, in our subgroup of patients treated with ADT, neither TMPRSS2-ERG fusion nor ERG overexpression predicted outcome. Additionally, the analysis of those patients treated without ADT also showed no predictive value of
TMPRSS2-ERG status. (See hazard ratio values associated with Kaplan-Meir plots in Supplementary Figures 4 and 5).
Given our goal to analyze IGRT patient outcome on the basis of aCGH or ERG overexpression as a prognostic versus predictive factor, we additionally determined whether fusion status was prognostic in a radical prostatectomy cohort in a similar lowto intermediate-risk cohort using a published dataset (36) . Details for this surgical cohort were previously described (26) . In this cohort, neither TMPRSS2-ERG fusion (by aCGH) 
DISCUSSION
To our knowledge, this is the first study to address the role of TMPRSS2-ERG status in pre-treatment biopsies of PCa patients treated with radical radiotherapy, one of the main treatment options for this disease. This is a pre-requisite to using this information to personalize treatment at the time of diagnosis. Our clinical data shows that TMPRSS2-ERG status, assayed using ERG overexpression or by aCGH, is not prognostic factor for biochemical recurrence after IGRT. This was also true for a small sub-group of patients treated with neoadjuvant and concurrent high-dose (150 mg per day) bicalutamide. Given recent data in surgical cohorts, this suggests that TMPRSS2-ERG status is not a determinant of recurrence following precision local therapies.
There are two main pathways of DSB repair: (1) non-homologous end-joining (NHEJ) in which a defect in this pathway leads to profound radiosensitivity and (2) homologous recombination (HR) in which less profound, but still appreciable, radiosensitivity is observed. (39) Our study has a number of limitations. Given the multi-focality and molecular heterogeneity of PCa, one possible weakness of our analysis is that aCGH data was based on only one biopsy to an index lesion (26) 
increasing risk of failure following IGRT (i.e. radioresistant phenotype) which would still argue against the hypothesis that fusion status is a marker of defective DSB repair associated with tumor cell radiosensitivity.
In the future, it would be advantageous to collect post-IGRT biopsies for all patients in order to better define the role of fusion status in terms of local control versus systemic relapse. Karnes et al. have proposed that ERG positive patients present a better response to androgen deprivation (38) and recently, TMPRSS2-ERG status has been shown to be a predictive biomarker for androgen therapy in the form of abiraterone. (47) As such, our results could differ in patients receiving combined-modality therapy as the primary treatment (e.g. high-risk or locally-advanced PCa) in which fusion status could be studied in the context of the need for salvage ADT (including enzalutamide or abiraterone) or systemic chemotherapy. These concepts could be investigated in tissues Mean equivalent dose was calculated using Biologically Effective Dose (BED) formula at 2Gy-daily fractions with an α/β ratio of 1.5 for tumor response. 
